Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Caplin Point Laboratories Ltd — Q4 FY26
Caplin Point delivered a strong FY26 with revenue doubling over five years to ₹2,300 crore and liquid assets tripling to ₹2,726 crore.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Caplin Point delivered a strong FY26 with revenue doubling over five years to ₹2,300 crore and liquid assets tripling to ₹2,726 crore. PAT grew 20% ahead of revenue growth of 13%, reflecting operating leverage. The US subsidiary (CSL) posted EBITDA margins of 30% for FY26, with own-label revenue nearing ₹100 crore in its first full year. Management guided for 25-30% growth in CSL next year and aims to double own-label sales to ~₹200 crore. Key drivers include 17 injectable lines coming online over 2-3 years, expansion in Latin America (Chile, Mexico), and a strong pipeline of 60 ANDAs. Risks include execution delays in capacity expansion and potential margin pressure from input cost inflation, though management believes its anti-fragile inventory model mitigates disruptions.
कैप्लिन पॉइंट ने वित्त वर्ष 2026 में शानदार प्रदर्शन किया। पिछले पांच सालों में कंपनी की कमाई दोगुनी होकर ₹2,300 करोड़ हो गई, और नकद संपत्ति तीन गुना बढ़कर ₹2,726 करोड़ पहुंच गई। मुनाफा (PAT) 20% बढ़ा, जो कमाई की 13% बढ़ोतरी से ज्यादा है - इसका मतलब कंपनी ने लागत पर अच्छा नियंत्रण रखा। अमेरिकी सहायक कंपनी (CSL) ने 30% का मुनाफा मार्जिन हासिल किया, और अपने ब्रांड की बिक्री पहले साल में ₹100 करोड़ के करीब पहुंच गई। अगले साल CSL में 25-30% और अपने ब्रांड की बिक्री ₹200 करोड़ तक बढ़ाने का लक्ष्य है। नए इंजेक्शन उत्पाद, लैटिन अमेरिका में विस्तार और 60 नई दवा अनुमतियां मुख्य कारण हैं। जोखिमों में उत्पादन में देरी और लागत बढ़ना शामिल है, लेकिन कंपनी का कहना है कि उसका मजबूत इन्वेंट्री मॉडल इसे संभाल लेगा।
Promises0 met · 1 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Receivable days increase
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US own-label revenue
₹100 crore
+100% YoY (first full year)
Own-label business reached ~₹100 crore in first full year; target to double to ~₹200 crore next year.
CSL EBITDA margin
30%
+200bps YoY
CSL EBITDA margin improved to 30% for FY26 from 27.97% in FY25.
ANDAs held
60
+25 YoY (10 approvals + 15 acquisitions)
Total ANDA count reached 60, with 10 approvals and 15 acquired in FY26.
Chile tender wins
$10 million
new
Won 35 products worth $10 million for supply over next 18 months in Chile.
What Changed vs Last Quarter
NEW
CSL overall growth 25-30% in FY27
Management expects the US subsidiary (CSL) to grow 25-30% in the coming year, driven by existing products and new launches.
NEW
Own-label revenue target ~₹200 crore in FY27
Aim to double own-label revenue from ~₹100 crore to ~₹200 crore in the next fiscal year.
NEW
Capex of ~₹500 crore over next 18-24 months
Remaining capex of about ₹500 crore to be spent on injectable plant phase 3, oral solids/derma facility, and oncology API plant.
NEW
17 injectable lines in 2-3 years
Company plans to have 17 injectable lines for US and regulated markets, with most machines imported from Germany and Italy.
DROPPED
High double-digit revenue growth for Caplin Steriles USA
Expect high double-digit revenue growth in the next years for Caplin Steriles and Caplin USA.
DROPPED
12-13 ophthalmic and prefilled syringe products for approval by end of next year
Expect to complete at least 12-13 products in ophthalmic and prefilled syringe range within next 12 months, coming up for approval by end of next year.
DROPPED
First DMF filing from Vizag API plant by end of this year
Targeting first DMF filing from Vizag API plant by end of this year, with 2-3 more APIs scaled up monthly.
DROPPED
PAT margin to remain in 26-29% range
Management expects PAT margin to stay in the 26-29% path, with potential for improvement as new initiatives fire.
NEW RISK
Receivable days increase
Receivable days rose to ~136 days (11 days due to forex revaluation), partly from a large El Salvador tender. Management expects normalization by Q2 FY27.
NEW RISK
Input cost inflation from tariffs
US tariffs on Chinese APIs and raw materials could increase COGS. Management noted highest impact product saw <2% COGS increase, but broader escalation remains a risk.
NEW RISK
Execution risk in capacity expansion
Large capex program (₹500 crore residual) and new injectable lines may face delays or regulatory hurdles, impacting growth timelines.
RISK GONE
Oncology facility delays
Oncology injectable plant has been delayed from Q1 FY27 to Q3 FY27 due to ecosystem challenges in Tamil Nadu, potentially impacting revenue timelines.
RISK GONE
Slower top-line growth vs capex
Despite doubling fixed assets in 2.5-3 years, top line grew only 40-50%, raising concerns about asset turnover and return on capex.
RISK GONE
Execution risk in new markets
Mexico and Chile markets are still 18-24 months away from meaningful revenue contribution, with tender-heavy dynamics and regulatory hurdles.
RISK GONE
GLP-1 opportunity uncertainty
GLP-1 market in developing regions is nascent; management admits being in the 'second wave' and the space is 'unknown' with unclear adoption.
Fast read
Guidance and risk preview
Management expects the US subsidiary (CSL) to grow 25-30% in the coming year, driven by existing products and new launches.
Receivable days rose to ~136 days (11 days due to forex revaluation), partly from a large El Salvador tender.
View Risks →